Ralf Weiskirchen

Institute of Clinical Chemistry and Pathobiochemistry, RWTH-University Hospital Aachen, Germany

Ralf Weiskirchen
Institute of Clinical Chemistry and Pathobiochemistry
RWTH University Hospital Aachen
Pauwelsstr. 30
D-52074 Aachen
Germany

Phone: +49 241-80 88683
Telefax: +49 241-80 82512
E-mail: rweiskirchen@ukaachen.de


Education and Degrees:
(1970-1974) Primary school, Katholische Grundschule in Bergisch Gladbach (NRW)
(1974-1983) Secondary school, Dietrich-Bonhoeffer-Gymnasium in Bergisch
(1983-1989) University of Cologne, Studies in Biology
(1988-1989) Diploma thesis at the Institute of Biochemistry, Faculty of Science, University of Cologne
(1989-1990) Alternative service at the Institute of Clinical Chemistry, Medical Faculty, University Hospital of Cologne
(1990-1994) Doctoral thesis (PhD) at the Institute of Biochemistry, Medical Faculty, University of Cologne
(1994) PhD thesis (summa cum laude)
(2001) Habilitation and Venia legendi in Pathobiochemistry and Molecular Biology
(2007) Professor assignment

Professional Positions:
(1988-1989) Student assistant at the Institute of Biochemistry, Faculty of Science, University of Cologne
(1989-1990) Research assistant at the Institute of Clinical Chemistry, Medical Faculty, University Hospital of Cologne
(1990-1993) Scientific research assistant, Institute of Biochemistry, Medical Faculty, University of Cologne
(1994-1999) Scientific staff member (Post-Doc), Institute of Biochemistry, Faculty of Science, University of Innsbruck (Austria)
(since 1999) Staff member, Institute of Clinical Chemistry and Pathobiochemistry, Medical Faculty, University Hospital Aachen

Main Research Areas:
- Functional analysis of PDGF and TGF-beta signaling in hepatic fibrogenesis
- Development of novel therapeutic strategies for the treatment of liver fibrosis
- Characterisation of novel animal models for the study of organ fibrosis
- Transcriptional targeting of hepatic stellate cells
- Functional and structural analysis of LIM domain proteins (e.g. CRP2)
- Development of novel, gene-based tests for analysis fibrosis progression and predisposition
- Adenoviral expression technology

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Gastroenterology & Hepatology > Liver Biology & Pathobiology (since 25 October 2007)

Links

http://www.ukaachen.de/content/folder/5095184

All recent recommendations

• 3.0
  RNA interference targeting the platelet-derived growth factor receptor beta subunit ameliorates experimental hepatic fibrosis in rats.
  Recommended by Ralf Weiskirchen with Erawan Borkham-Kamphorst
  
• 9.9
  Senescence of activated stellate cells limits liver fibrosis.
  Recommended by Ralf Weiskirchen with Jens Herrmann, Rebecca Wells, Steven Dooley
  
• 9.0
  In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.
  Recommended by Ralf Weiskirchen with Jens Herrmann
  
• 3.0
  Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin.
  Recommended by Ralf Weiskirchen with Steffen K Meurer
  
• 4.8
  Telbivudine versus lamivudine in patients with chronic hepatitis B.
  Recommended by Ethan Rubinstein with Philippe Lagacé-Wiens, Ralf Weiskirchen with Frank Tacke
  
• 9.0
  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.
  Recommended by Ralf Weiskirchen with Steffen K Meurer
  
• 3.0
  The T/G 13915 variant upstream of the lactase gene (LCT) is the founder allele of lactase persistence in an urban Saudi population.
  Recommended by Ralf Weiskirchen with Catherine J. E. Ingram and Dallas M. Swallow
  
• 10.1
  TLR4 enhances TGF-beta signaling and hepatic fibrosis.
  Recommended by Ralf Weiskirchen with Falko Drews, Rebecca Wells with Zhaodong Li, Philipp M Lepper, Steven Dooley
  
• 3.0
  A rapid and sensitive bioassay to measure bone morphogenetic protein activity.
  Recommended by Ralf Weiskirchen